Trial Search Results

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

The primary objectives of this study are:

- To investigate the safety and tolerability, and to define the recommended Phase 2 dose and schedule (RP2DS) for magrolimab in combination with rituximab and for magrolimab in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx).

- To evaluate the efficacy of magrolimab in combination with rituximab in participants with indolent lymphoma and diffuse large B-cell lymphoma (DLBCL) and to evaluate the efficacy of magrolimab in combination with R-GemOx in aspartate aminotransferase (ASCT) ineligible DLBCL participants.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Gilead Sciences

Collaborator: The Leukemia and Lymphoma Society

Stanford Investigator(s):

Intervention(s):

  • Drug: Magrolimab
  • Drug: Rituximab
  • Drug: Gemcitabine
  • Drug: Oxaliplatin

Phase:

Phase 1/Phase 2

Eligibility


Key Inclusion Criteria:

   - Phase 1b only: B-cell non-Hodgkin's lymphoma (NHL), relapsed or refractory to standard
   approved therapies

   - DLBCL Phase 2 cohort: De novo or transformed diffuse large B-cell lymphoma (DLBCL)
   expressing CD 20, relapsed or refractory to at least 2 prior lines treatment
   containing anti-CD20 therapy

   - Indolent lymphoma Phase 2 cohort: Marginal zone or follicular lymphoma, relapsed or
   refractory to standard approved therapies

   - DLBCL chemotherapy combination cohort: De novo or transformed diffuse large B-cell
   lymphoma (DLBCL), relapsed or refractory to 1-3 prior lines of treatment

   - Adequate performance status and hematological, liver and kidney functions

   - Willing to consent to 1 mandatory pre-treatment and 1 on-treatment tumor biopsy

Key Exclusion Criteria:

   - Active brain metastases

   - Prior allogeneic hematopoietic cell transplantation

   - Prior treatment with CD47 or signal regulatory protein alpha (SIRPα) targeting agents

   - Second malignancy within the last 3 years

   - Known active or chronic hepatitis B or C infection or HIV

   - Pregnancy or active breastfeeding

   - Prior chimeric antigen receptor (CAR-T) therapy

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Canaan Muluneuh
650-725-6432
Recruiting